---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-000313"
form_type: "8-K"
ticker: "COSM"
cik: "0001474167"
company_name: "Cosmos Health Inc."
filed_at: "2024-01-22T23:59:59+00:00"
generated_at: "2026-06-06T20:36:52.060650+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cosmos Health acquires 10 generic drug portfolio for $3.5M from related party

## Summary
- Acquired licenses/rights to 10 generic drugs from related party for €3.2M ($3.5M).
- Drugs target diabetes, cholesterol, respiratory, cardiac conditions and more.
- Manufacturing to occur at Cosmos' wholly-owned subsidiary Cana Laboratories.
- Global generic drugs market valued at $411.99B in 2022, projected to $613.34B by 2030.
- CEO says acquisition supports transition to full-fledged pharmaceutical company.

## SEC filing metadata
- accession: 0001477932-24-000313
- form_type: 8-K
- ticker: COSM
- cik: 0001474167
- company_name: Cosmos Health Inc.
- filed_at: 2024-01-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1474167/000147793224000313/0001477932-24-000313-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1474167/000147793224000313/cosm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-000313
- JSON: https://secwatch.observer/filing/0001477932-24-000313.json
- Plain text: https://secwatch.observer/filing/0001477932-24-000313.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.